CREB-H is an endoplasmic reticulum-bound transcription factor that is highly and selectively expressed only in the liver and the small intestine ( Supplementary Fig. 1a,b) 1, 2 . Its activation requires a sequential cleavage of the precursor protein by Golgi proteases that liberate the mature N-terminal portion of the protein, which localizes to the nucleus to act as a transcriptional transactivator 3, 4 . It has been recently demonstrated that Creb3l3 mRNA synthesis is induced by metabolic cues such as fasting, fatty acids and peroxisome proliferator-activated receptor-α, suggesting that it might participate in nutrient and energy metabolism 5, 6 .
To gain insight into the role of CREB-H in nutrient metabolism, we measured the metabolic parameters of CREB-H-deficient Creb3l3 −/− mice 1 (Supplementary Methods). We found that Creb3l3 −/− mice had higher plasma triglyceride concentrations compared to wildtype (WT) mice (Fig. 1a) , suggesting that CREB-H regulates triglyceride metabolism. Plasma concentrations of free fatty acid (FFA) and cholesterol were slightly changed in Creb3l3 −/− mice (Fig. 1a) . Fractionation of plasma lipoproteins by density gradient ultracentrifugation indicated that the very-low-density lipoprotein (VLDL) fraction of Creb3l3 −/− mice had higher triglyceride content compared to that of WT mice (Fig. 1b) . In line with the induction of the processed nuclear form of CREB-H (CREB-H(N)) by fasting in the liver (Supplementary Fig. 1c,d) , the hypertriglyceridemia phenotype of Creb3l3 −/− mice was exacerbated upon prolonged starvation (Fig. 1c) . Fasting-induced hepatic steatosis was also more pronounced in Creb3l3 −/− mice than in WT mice (Fig. 1d) . Consistent with higher VLDL triglyceride content in Creb3l3 −/− mice versus WT mice, the plasma Apob level was also higher in Creb3l3 −/− than in WT mice (Fig. 1e) . Notably, Apoc3, an inhibitor of Lpl, was abundant in VLDL particles purified from Creb3l3 −/− plasma, as determined by mass spectrometry and western blotting (Fig. 1e,f) .
Fasting plasma triglyceride concentration reflects a balance between the production of VLDL from the liver and the clearance of triglyceride-rich lipoproteins from the circulation, governed predominantly by Lpl present on the surface of vascular endothelium in various organs 7 . To determine whether CREB-H is involved in VLDL secretion from the liver, we measured the rate of triglyceride accumulation in plasma after administration of an Lpl inhibitor, tyloxapol. The VLDL secretion rate was not considerably different between WT and Creb3l3 −/− mice (Fig. 1g) , arguing against a role for CREB-H in VLDL secretion.
We next examined whether CREB-H deficiency led to decreased Lpl-mediated triglyceride clearance. Olive oil gavage resulted in more pronounced hypertriglyceridemia in Creb3l3 −/− mice than in WT mice (Fig. 1h) , suggesting a defect in triglyceride clearance in the absence of CREB-H. Creb3l3 −/− mice showed lower plasma Lpl activity after heparin administration, which releases Lpl from vascular endothelium, compared to WT mice (Fig. 1i) , despite normal Lpl mRNA levels in adipose tissue and skeletal muscle (Supplementary Fig. 2 ), suggesting that plasma cofactors for Lpl might be limiting in Creb3l3 −/− mice. Consistent with this idea, the addition of WT serum as a source of Apoc proteins significantly increased the Lpl activity retained in plasma of Creb3l3 −/− mice after heparin treatment (Fig. 1i) . The potency of Creb3l3 −/− serum in augmenting Lpl-mediated hydrolysis of triolein substrate was also attenuated compared to that of WT serum (Fig. 1j) . Further, transfusion of WT but not Creb3l3 −/− plasma efficiently reduced triglyceride levels in Creb3l3 −/− mice ( Supplementary  Fig. 3a) . Collectively, these data establish that the hypertriglyceridemia observed in Creb3l3 −/− mice is a consequence primarily of decreased triglyceride clearance from plasma, rather than increased triglyceride output from the liver.
To identify CREB-H target genes that might contribute to the hypertriglyceridemia phenotype of Creb3l3 −/− mice, we performed a microarray analysis of RNAs isolated from WT and Creb3l3 −/− mouse liver (Supplementary Fig. 2b) 8 . Hepatic Fgf21, Apoa4, Elov5 and G0s2 levels were also lower in Creb3l3 −/− than in WT mice (Fig. 2a) . Fgf21, a member of the fibroblast growth factor family, is induced by fasting in mouse liver and reduces plasma triglyceride levels 9 . Fads and Elovl genes encode a fatty acid desaturase and elongase, respectively, which have key roles in the synthesis of long-chain polyunsaturated fatty acids and the regulation of fatty acid metabolism 10 . G0s2 and Cidec are induced in the liver by fasting and are known to regulate triglyceride hydrolysis and lipid droplet formation, respectively 11, 12 . Apoa4, Apoa5, Apoc2 and Fgf21 were induced in WT liver by fasting, an effect that was abrogated in Creb3l3 −/− mice (Fig. 2b) . Apoa4 and Apoc2 are normally highly expressed in mouse small intestine. Intestinal mRNA levels of these genes were also lower in Creb3l3 −/− compared to WT mice ( Supplementary Fig. 2c ). Lower plasma Apoa4 protein amounts in Creb3l3 −/− compared to WT mice correlated well with Apoa4 mRNA levels in the liver and the intestine (Supplementary Fig. 2d ). Apoa5 and Apoc2 activate Lpl, whose activity is further augmented by Apoa4, to facilitate the delivery of hydrolyzed fatty acids to peripheral cells and hence to lower plasma triglyceride abundance 13, 14 . Despite markedly higher Apoc3 levels in the VLDL fraction of Creb3l3 −/− mice than in that of WT mice, Apoc3 mRNA levels were not significantly different between these two groups ( Supplementary  Fig. 2e ), suggesting post-transcriptional control of Apoc3 by CREB-H. We postulate that the concomitant reduction in expression of the Lpl activators Apoa4, Apoa5 and Apoc2 and induction of the Lpl inhibitor Apoc3 impairs triglyceride clearance, resulting in higher plasma triglyceride concentrations in Creb3l3 −/− compared to WT mice. Indeed, injection of recombinant Apoc2 effectively reduced plasma triglyceride levels in Creb3l3 −/− mice (Supplementary Fig. 3b ). In contrast, Apoc2 injection only modestly decreased plasma triglyceride levels in WT mice.
To identify additional CREB-H target genes involved in triglyceride metabolism, we generated transgenic mice that overexpressed a constitutively active CREB-H(N) in the liver (Supplementary Fig. 4a ). Both the endogenously processed and the transgenic CREB-H(N) were expressed as 42-kDa proteins in the liver (Supplementary Fig. 4b) . Hepatic CREB-H(N) protein amounts were 14-fold higher in the transgenic mice compared with WT littermates, despite the fact that the transgenic mRNA level was only 1.25-fold higher than the endogenous Creb3l3 (Supplementary Fig. 4c ), suggesting that ~10% of CREB-H protein is basally processed to the mature form in the liver of normalchow-diet-fed WT mice. CREB-H(N) overexpression strongly induced Apoc2, Apoa4, Fgf21 and Cidec mRNA expression ( Supplementary  Fig. 4d ), mirroring the downregulation of these genes in Creb3l3 −/− mice. Other apolipoprotein genes located within the same gene clusters as Apoc2 and Apoa4 on chromosomes 7 and 9, respectively, were unaffected by CREB-H(N) overexpression in the transgenic liver ( Supplementary Fig. 4d,e) . Notably, plasma triglyceride levels were significantly lower in CREB-H(N)-transgenic mice than in WT littermates, in contrast to the hypertriglyceridemic phenotype of Creb3l3 −/− mice (Supplementary Fig. 4f ). CREB-H(N) overexpression by adenoviral infection also lowered plasma triglyceride concentrations in mice, concomitantly increasing the potency of the serum to stimulate LPL in an in vitro assay (Supplementary Fig. 4g,h ). Transient transfection assays showed that CREB-H strongly transactivated the Apoa4, Apoc2 and Fgf21 promoters (Supplementary Fig. 4i ), indicating transcriptional activation of these genes by CREB-H. Emerging evidence suggests that complex traits such as plasma cholesterol and triglyceride concentrations are contributed by both common and rare genetic variants 8, 15 . Common variants in CREB3L3 were not observed to be associated with plasma triglyceride concentrations in recent large genome-wide association studies in humans 16 . As CREB-H deficiency caused a dramatic increase in plasma triglyceride concentrations with no other overt abnormalities in mice, we asked whether mutations in CREB3L3 could similarly contribute to hypertriglyceridemia in humans. Hence, we searched for rare mutations in the CREB3L3 gene in an established clinical cohort with hypertriglyceridemia 17 . We sequenced CREB3L3 coding regions in 449 unrelated individuals with hypertriglyceridemia of European ancestry (triglyceride concentration > 3.37 mM) with no disease-associated SNPs in LPL, APOC2 and APOA5 genes, as well as in 238 matched normolipidemic controls (triglyceride concentration < 2.3 mM) 17 . Heterozygous nonsynonymous or insertional mutations in CREB3L3 were identified in 12 of 449 individuals with hypertriglyceridemia but were completely absent from the 238 controls (P = 0.01, two-sided Fisher's exact test, Supplementary Table 2 ). In contrast, synonymous variants had similar frequency in hypertriglyceridemia and control groups (13 of 238 control versus 12 of 449 hypertriglyceridemia, P = 0.22). All mutations localized to the N-terminal region of the protein preceding the bZIP domain (Fig. 2c) . Three unrelated individuals with hypertriglyceridemia were heterozygous for the same complex mutation (designated 245fs), which consisted of a G insertion in the first nucleotide of codon 245 together with a A→T point mutation seven nucleotides downstream (Supplementary Fig. 5a ). One individual with hypertriglyceridemia was heterozygous for the nonsense CREB3L3 W46X mutation. Eight hypertriglyceridemia probands had heterozygous missense mutations, which included two probands with G105R, two with P166L, one with V180M, one with D182N and two with E240K mutations (clinical features are summarized in Supplementary Table 2 ). Lipoprotein profiles of the nuclear families of the four individuals with CREB3L3 nonsense mutations showed a significantly elevated mean plasma triglyceride level in 11 mutation carriers compared with five noncarrier first-degree relatives (9.67 ± 4.70 mM versus 1.66 ± 0.55 mM, P = 0.021, Wilcoxon test) ( Supplementary  Fig. 5b ). Finally, low-coverage resequencing of 179 additional multiethnic genomes in the 1,000 Genomes Project identified only the G105R variant from our sample and one additional variant not observed in our sample 18 , suggesting that occurrence of nonsynonymous variants in CREB3L3 is extremely rare in normolipidemic populations.
We evaluated the function of the mutant CREB-H proteins encoded by these human variants in transactivation assays using luciferase reporters driven by the proximal Apoa4, APOC2 or Fgf21 promoters. The W46X and 245fs mutations precluded translation of the DNA binding and bZIP domains, and, as expected, the resulting mutant proteins failed to transactivate any of the reporters (Fig. 2d) . The E240K mutation also severely abrogated the induction of all reporters by CREB-H(N) cotransfection. The D182N mutation caused modest but reproducible decreases in fold inductions on all reporters, whereas V180M did so only on the Apoc2 reporter (Fig. 2d) . In contrast, the G105R and P166L mutations did not significantly affect CREB-H transactivation of the promoters tested (Fig. 2d) . The precise effects of these mutations on the function of CREB-H and their contribution, if any, to the elevated triglyceride concentrations in the carriers remain to be investigated. In summary, we have shown that rare heterozygous variants in CREB3L3 are significantly associated with the polygenic trait of hypertriglyceridemia, similar to other established hypertriglyceridemia-associated genes such as APOA5 and LPL 17 .
In this report, we identify CREB-H as a transcription factor that has a crucial role in triglyceride metabolism. CREB-H is induced by fasting in the liver and is required for the expression of a series of genes that are involved in triglyceride metabolism, which include Apoa4, Apoa5, Apoc2, Cidec, Elovl2, Elovl5, Fads1, Fads2, Fgf21 and G0s2. Creb3l3 −/− mice show hypertriglyceridemia and a defect in Lplmediated triglyceride clearance, which might be ascribed to defective expression of Apoc2, Apoa4 and Apoa5 coupled with the augmentation of VLDL-associated Apoc3 and with contributions from other yet-to-be-identified CREB-H targets. We further discovered hypomorphic or null mutations in CREB3L3 that were associated with hypertriglyceridemia in humans, implicating a key role for CREB-H in human triglyceride metabolism. The causal relationship between CREB3L3 variations and hypertriglyceridemia remains to be determined. It will be informative to test whether mutant mice harboring any CREB3L3 mutations found in individuals with hypertriglyceridemia are predisposed to develop a similar condition. It will also be of interest to investigate the correlation between plasma triglyceride concentrations and the frequency of CREB3L3 sequence variations and their effects on CREB-H function in larger and more diverse human populations. CREB-H is structurally related to sterol regulatory elementbinding proteins, which play major parts in triglyceride and cholesterol biosynthesis in the liver, as they are synthesized as endoplasmic reticulum-localizing precursor proteins and activated by S1P and S2P proteases in the Golgi apparatus 3, 19 . CREB-H is also functionally related to peroxisome proliferator-activated receptor α, which has a role in fatty acid oxidation in the liver 20 , as both genes are induced by fasting and have common targets such as Fgf21, Apoa5 and G0s2. Future studies will address the molecular mechanisms by which CREB-H is activated and regulates triglyceride homeostasis in concert with other transcriptional regulatory proteins. Elucidation of the signaling pathways that activate CREB-H may lead to new therapeutic targets to treat human dyslipidemias.
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